{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:27:37Z","timestamp":1764937657549,"version":"3.37.3"},"reference-count":10,"publisher":"American Society of Hematology","issue":"26","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,28]]},"DOI":"10.1182\/blood.2023022382","type":"journal-article","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T16:37:37Z","timestamp":1703781457000},"page":"2232-2234","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Tribulations of trials in aggressive lymphoma"],"prefix":"10.1182","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1615-0540","authenticated-orcid":false,"given":"Allison","family":"Barraclough","sequence":"first","affiliation":[{"name":"1Fiona Stanley Hospital"},{"name":"2University of Melbourne"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0376-2559","authenticated-orcid":false,"given":"Eliza A.","family":"Hawkes","sequence":"additional","affiliation":[{"name":"2University of Melbourne"},{"name":"3Austin Health"},{"name":"4Monash University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"26","key":"2023122816372877500_bib1","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1182\/blood.2023021274","article-title":"Tafasitamab and lenalidomide in large B cell lymphoma: real-world outcomes in a multicenter retrospective study","volume":"142","author":"Qualls","year":"2023","journal-title":"Blood"},{"issue":"4","key":"2023122816372877500_bib2","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/bjh.17436","article-title":"Evolution of eligibility criteria for diffuse large B-cell lymphoma randomised controlled trials over 30 years","volume":"193","author":"Loh","year":"2021","journal-title":"Br J Haematol"},{"issue":"15","key":"2023122816372877500_bib3","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1200\/JCO.20.01935","article-title":"Impact of organ function-based clinical trial eligibility criteria in patients with diffuse large B-cell lymphoma: who gets left behind?","volume":"39","author":"Khurana","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2023122816372877500_bib4","doi-asserted-by":"crossref","first-page":"E117-E116","DOI":"10.1002\/ajh.25411","article-title":"Eligibility for CAR T-cell therapy: an analysis of selection criteria and survival outcomes in chemorefractory DLBCL","volume":"94","author":"Smith","year":"2019","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"2023122816372877500_bib5","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1182\/blood-2022-156376","article-title":"Impact of trial eligibility criteria on outcomes of 1,245 patients with follicular lymphoma treated in the real-world setting: a Danish population-based study","volume":"140","author":"Bennedsen","year":"2022","journal-title":"Blood"},{"issue":"16_suppl","key":"2023122816372877500_bib6","doi-asserted-by":"crossref","first-page":"7552","DOI":"10.1200\/JCO.2023.41.16_suppl.7552","article-title":"Real-world outcomes with novel therapies in R\/R DLBCL","volume":"41","author":"Crombie","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"2023122816372877500_bib7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/bjh.18197","article-title":"Outcomes of relapsed\/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line\u2014a population-based study of 736 patients","volume":"198","author":"Harrysson","year":"2022","journal-title":"Br J Haematol"},{"issue":"S3","key":"2023122816372877500_bib8","doi-asserted-by":"crossref","first-page":"e24670ab","DOI":"10.1097\/01.HS9.0000971668.24670.ab","article-title":"Polatuzumab, bendamustine & rituximab (Pola-BR) efficacy in relapsed\/refractory diffuse large B-cell lymphoma (RR-DLBCL) trial ineligible patients: an Australian lymphoma registry (LARDR) study","volume":"7","author":"Shaw","year":"2023","journal-title":"HemaSphere"},{"issue":"7","key":"2023122816372877500_bib9","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamainternmed.2019.0462","article-title":"Assessment of the clinical benefit of cancer drugs receiving accelerated approval","volume":"179","author":"Gyawali","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"5","key":"2023122816372877500_bib10","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(22)00200-5","article-title":"The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint","volume":"23","author":"Richardson","year":"2022","journal-title":"Lancet Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/26\/2232\/2178028\/blood_bld-2023-022382-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/26\/2232\/2178028\/blood_bld-2023-022382-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T16:37:52Z","timestamp":1703781472000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/142\/26\/2232\/506638\/Tribulations-of-trials-in-aggressive-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,28]]},"references-count":10,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2023,12,28]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023022382","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"type":"print","value":"0006-4971"},{"type":"electronic","value":"1528-0020"}],"subject":[],"published":{"date-parts":[[2023,12,28]]}}}